The stock of Revance Therapeutics Inc (RVNC) has gone up by 3.99% for the week, with a -21.96% drop in the past month and a -33.48% drop in the past quarter. The volatility ratio for the week is 6.07%, and the volatility levels for the past 30 days are 6.54% for RVNC. . The simple moving average for the past 20 days is -6.73% for RVNC’s stock, with a -59.14% simple moving average for the past 200 days.
Is It Worth Investing in Revance Therapeutics Inc (NASDAQ: RVNC) Right Now?
Company’s 36-month beta value is 1.10.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVNC is 93.53M, and currently, short sellers hold a 11.62% ratio of that floaft. The average trading volume of RVNC on April 10, 2024 was 1.78M shares.
RVNC) stock’s latest price update
Revance Therapeutics Inc (NASDAQ: RVNC) has experienced a rise in its stock price by 5.39 compared to its previous closing price of 4.45. However, the company has seen a gain of 3.99% in its stock price over the last five trading days. Business Wire reported 2024-02-21 that NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024.
Analysts’ Opinion of RVNC
Many brokerage firms have already submitted their reports for RVNC stocks, with Mizuho repeating the rating for RVNC by listing it as a “Neutral.” The predicted price for RVNC in the upcoming period, according to Mizuho is $9 based on the research report published on January 29, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RVNC reach a price target of $8, previously predicting the price at $30. The rating they have provided for RVNC stocks is “Neutral” according to the report published on January 09th, 2024.
Exane BNP Paribas gave a rating of “Neutral” to RVNC, setting the target price at $20 in the report published on August 16th of the previous year.
RVNC Trading at -14.10% from the 50-Day Moving Average
After a stumble in the market that brought RVNC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.65% of loss for the given period.
Volatility was left at 6.54%, however, over the last 30 days, the volatility rate increased by 6.07%, as shares sank -25.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.31% lower at present.
During the last 5 trading sessions, RVNC rose by +3.99%, which changed the moving average for the period of 200-days by -82.67% in comparison to the 20-day moving average, which settled at $4.95. In addition, Revance Therapeutics Inc saw -46.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVNC starting from Schilke Tobin, who sale 9,361 shares at the price of $5.04 back on Mar 18 ’24. After this action, Schilke Tobin now owns 192,666 shares of Revance Therapeutics Inc, valued at $47,204 using the latest closing price.
Sjuts Dustin S, the President of Revance Therapeutics Inc, sale 9,211 shares at $5.04 during a trade that took place back on Mar 18 ’24, which means that Sjuts Dustin S is holding 167,550 shares at $46,446 based on the most recent closing price.
Stock Fundamentals for RVNC
Current profitability levels for the company are sitting at:
- -1.35 for the present operating margin
- 0.68 for the gross margin
The net margin for Revance Therapeutics Inc stands at -1.41. The total capital return value is set at -0.81. Equity return is now at value -2096.78, with -61.11 for asset returns.
Based on Revance Therapeutics Inc (RVNC), the company’s capital structure generated 1.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.5. The debt to equity ratio resting at -2.89. The interest coverage ratio of the stock is -16.32.
Currently, EBITDA for the company is -207.03 million with net debt to EBITDA at -1.66. When we switch over and look at the enterprise to sales, we see a ratio of 3.54. The receivables turnover for the company is 8.46for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.80.
Conclusion
In a nutshell, Revance Therapeutics Inc (RVNC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
